Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Taiwan · Delayed Price · Currency is TWD

83.50

-0.30 (-0.36%)

Mar 2, 2026, 1:30 PM CST

-2.57% (1Y)

Market Cap	13.20B
Revenue (ttm)	519.61M
Net Income (ttm)	-1.23B
Shares Out	157.54M
EPS (ttm)	-8.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	227,546
Average Volume	220,306
Open	82.80
Previous Close	83.80
Day's Range	81.90 - 83.70
52-Week Range	57.70 - 93.70
Beta	0.70
RSI	54.27
Earnings Date	Feb 24, 2026

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2013

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 6576

Full Company Profile

Financial Performance

In 2024, Foresee Pharmaceuticals's revenue was 418.69 million, an increase of 114.67% compared to the previous year's 195.04 million. Losses were -1.08 billion, 4.32% more than in 2023.

Financial Statements

News

There is no news available yet.